MaxCyte Inc. (NASDAQ:MXCT) reported its first-quarter 2025 earnings, showcasing a stronger-than-expected performance. The company posted a revenue of $10.4 million, surpassing the forecasted $9.05 ...

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization ...

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading ... of $4.5 million at closing in cash for the entire issued share capital of SeQure DX on a cash free, debt free basis using Maxcyte’s ...

MaxCyte added one new SPL client ... and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter ...

Here's a brief overview for investors ahead of the announcement. Analysts anticipate MaxCyte to report an earnings per share (EPS) of $-0.10. Anticipation surrounds MaxCyte's announcement ...

Shares of NASDAQ:BCAL opened at $14.89 on Friday. Southern California Bancorp has a twelve month low of $11.87 and a twelve month high of $18.49. The company has a market cap of $482.47 million ...

In the first quarter, Chart's sales rose 5.3% to $1.0 billion in sales, which slightly missed analysts' consensus expectations, while adjusted (non-GAAP) earnings per share rose by a strong 38.8% ...

The company's earnings came in at $49.5 million, or $0.94 per share. This compares with $11.3 million, or $0.10 per share, last year. Excluding items, Chart Industries Inc. reported adjusted ...